ProCE Banner Activity

CAPTIVATE: Updated Results From the Phase II Trial of First-line Ibrutinib Plus Venetoclax for CLL/SLL

Slideset Download
Conference Coverage
Initial therapy with ibrutinib + venetoclax for 12 cycles resulted in a 1-year DFS rate of 95.3% in patients with uMRD who were subsequently randomized to placebo.

Released: December 14, 2020

Expiration: December 13, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology